

Review Article

Hospital-Acquired Infections in the Age of Antimicrobial Resistance and Smart Surveillance

Olabisi Promise Lawal¹, Idris Olumide Orenolu², Morayo Anne Ajobiwe³, Kwesi Akonu Adom Mensah Forson⁴, Ujunwa Favour Agu⁵, Moses Emmanuel Fidelix⁶, Frances Chinaehekwa Madugba⁷, Lenin Ifeanyi Obi⁸

¹Department of Medical Laboratory Science, University of Benin, Benin City, Nigeria

²Infection Prevention and Control, Saskatchewan Health Authority, Saskatchewan, Canada

³Nursing Program, Faculty of Health Sciences, University of Lethbridge, Lethbridge, Alberta, Canada

⁴Department of Biology, University of Virginia, Charlottesville, USA

⁵Department of Nursing Sciences, Faculty of Allied Health Sciences, Enugu State University of Science and Technology, Enugu State, Nigeria

⁶Department of Medical Laboratory Science, University of Benin, Benin City, Nigeria

⁷Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Benin, Benin City, Nigeria

⁸Department of Nursing Science, Ladoke Akintola University of Technology, Ogbomoso, Nigeria

Received: Aug 07, 2025

Accepted: Aug 13, 2025

Corresponding author's email:

lawalolabisipromise@gmail.com



This work is licensed under a
Creative Commons Attribution 4.0
International License

Abstract:

Hospital-acquired infections (HAIs) continue to be one of the biggest problems for modern healthcare systems, and the problem is getting worse because antimicrobial resistance (AMR) is on the rise. Antibiotics that used to work are quickly losing their effectiveness, which is giving rise to highly adaptable bacteria in clinical settings and turning routine procedures into high-risk situations. This publication examines the intersection of healthcare-associated infections (HAIs) and antimicrobial resistance (AMR) within the framework of smart surveillance—digital, data-driven systems engineered to identify, predict, and disrupt the spread of infections in real time. We examine the historical development of infection surveillance, analyze the epidemiological burden and resistance mechanisms contributing to a covert pandemic, and assess emerging technologies such as electronic health record integration, machine-learning analytics, genomic sequencing, and Internet of Things (IoT) sensor networks. These new ideas give us new ways to prevent infections before they happen, but they also bring up difficult moral, legal, and social problems about privacy, fairness, and governance. We contend that intelligent surveillance should be integrated into comprehensive infection prevention frameworks and antimicrobial stewardship initiatives to establish resilient hospitals. By combining predictive analytics with basic IPC procedures, ethical monitoring, and giving workers more autonomy, healthcare organizations may turn passive surveillance into active defense. In the end, winning the war against HAIs will depend not just on cutting-edge technology, but also on how it is used with care, honesty, and openness.

Keywords: Hospital-acquired infections; Antimicrobial resistance; Smart surveillance; Predictive analytics; Infection prevention and control.

Introduction

Hospitals have long been seen as safe places with precise medical care, yet they have a strange problem: diseases thrive in sterile hallways and high-tech wards without anybody noticing. These Hospital-Acquired Infections (HAIs) are infections that weren't present or incubating when the patient was admitted, but show up 48 hours or more after they have been in the hospital [1]. They happen right where healing is meant to happen. HAIs are a deadly mix of life-saving medical care and microbial opportunism. They can happen when a ventilator causes pneumonia, a catheter causes a bloodstream infection, or a surgical site is contaminated.

In the age of Antimicrobial Resistance (AMR), this issue is no longer just procedural; it is now existential. As harmful germs evolve to and evade the pharmacological arsenal that previously controlled them, therapy options diminish. Methicillin-resistant *Staphylococcus aureus*, carbapenem-resistant *Pseudomonas* and *Enterobacterales*, and vancomycin-resistant *Enterococci* have become permanent residents of ICUs, turning hospitals into places where evolution happens [2]. The clinical impact is clear: traditional treatment is becoming less and less effective against HAIs, which makes people sick longer, costs more, and kills people with ruthless efficiency.

In light of this, a new tactic has begun to take shape: smart monitoring. Surveillance systems are changing from passive storage spaces to active tools for prediction, early detection, and strategic reaction by using digital health records, quick genetic tests, sensor networks, and artificial intelligence. The knowledge collected from these interconnected platforms promises to halt transmission chains, identify high-risk circumstances before epidemics occur, and personalize interventions with unprecedented precision [3]. While this paper examines HAIs in general to provide a comprehensive view of their intersection with AMR and smart surveillance, we recognize that focusing on a single high-impact pathogen—such as methicillin-resistant *Staphylococcus aureus* or carbapenem-resistant *Enterobacterales*—could allow for an even deeper analysis. This broader scope was chosen to capture commonalities across pathogens and inform surveillance strategies applicable to multiple resistant organisms.

We hypothesize that integrating smart surveillance technologies with established infection

prevention and antimicrobial stewardship strategies can significantly reduce the incidence and impact of antimicrobial-resistant HAIs in healthcare settings. The aim of this paper is to synthesize current evidence on HAIs and AMR, evaluate the role of smart surveillance technologies, and propose a conceptual framework for their integration into modern healthcare systems.

This paper contends that the convergence of antimicrobial resistance (AMR) and healthcare-associated infections (HAIs) in modern healthcare establishes a pressing necessity: only via the ethical and judicious implementation of advanced surveillance can we overcome the constraints of conventional infection control methods. By reimagining surveillance as a forward-thinking, tech-savvy part of hospital resilience, we might be able to get the upper hand on the silent killers that are in our wards. To better illustrate the complex interplay between infection risks, resistance dynamics, and technological interventions, we present a conceptual framework (Figure 1) highlighting their convergence in modern healthcare environments.




Figure 1. The Intersection of HAIs, AMR, and Smart Surveillance in Modern Healthcare. A conceptual Venn diagram illustrating the interconnected relationship between Hospital-Acquired Infections (HAIs), Antimicrobial Resistance (AMR), and Smart Surveillance. The overlapping areas highlight how these domains influence and reinforce each other. Ethical and legal considerations are depicted as an overarching layer affecting all three components.

The Epidemiological Burden of Hospital-Acquired Infections (HAIs)

The epidemiology of Hospital-Acquired Infections has changed a lot since the Crimean War, when Florence Nightingale first saw how bad hygiene could kill people. Now, hospitals have complex intensive care units full of invasive devices and patients with weakened immune systems [4]. In the 1800s, puerperal sepsis and gangrene were the most common diseases. This was mostly because people didn't practice good hygiene and didn't know how to use aseptic techniques [5].

Over time, the introduction of medicines and improvements in surgical techniques temporarily reduced these risks, but they also unintentionally created new habitats for more advanced infections. Changes in how vulnerable hosts are (older people, people with chronic illnesses, and people with weakened immune systems) and more complicated treatments (mechanical ventilation, indwelling catheters, organ transplantation) have changed the microbial battlefield, making hospitals perfect places for opportunistic infections [6].

HAIs are a big problem in today's world. The World Health Organization says that hundreds of millions of people around the world are affected each year, which means a lot of illness, extended hospital stays, and huge healthcare expenses [7]. In high-income countries, about 7–10% of hospitalized patients get at least one HAI. In low- and middle-income countries,

that number might be as high as 15–20%[8]. The Centres for Disease Control and Prevention says that HAIs cause more than 1.7 million illnesses and about 100,000 deaths in the US each year, costing between \$35 and \$45 billion [9]. These numbers hide big differences: tertiary hospitals with strong infection control systems do far better than rural or public hospitals that don't have enough resources and are overcrowded, have poor staffing ratios, and don't have enough surveillance. Regions with few resources, especially in sub-Saharan Africa and portions of South Asia, have a harder time containing and reporting problems, and they often have to deal with more of the problems than they should [10].

A group of pathogens that are very hard to kill is in charge of the worldwide HAI landscape. Methicillin-resistant *Staphylococcus aureus* (MRSA) continues to produce catastrophic infections in the bloodstream and at surgical sites, while Vancomycin-resistant *Enterococci* (VRE) tear through oncology wards [11]. Gram-negative species, including Carbapenem-resistant *Enterobacterales* (CRE), *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and extended-spectrum β -lactamase (ESBL)–producing bacteria, are causing more and more illnesses that can't be treated [2]. *Clostridioides difficile*, which grows when antibiotics kill off gut flora, is a major cause of nosocomial diarrhea, which can be quite dangerous for older people [12].

Table 1: Prevalence of Hospital-Acquired Infections in Selected Regions and Settings

| Region / Country | Study Design / Source | Reported Prevalence | Reference |
|--|---------------------------------------|--|---------------------------|
| High-income countries (overall) | WHO global review | 7–10% of hospitalized patients | WHO, 2025 [7] |
| Low- and middle-income countries (overall) | WHO global review | 15–20% of hospitalized patients | WHO, 2025 [7] |
| Nigeria | Cross-sectional, tertiary hospital | 16.9% point prevalence | Abubakar et al., 2022 [8] |
| Bangladesh | WHO IPCAF assessment in tertiary care | 11.6% average prevalence | Harun et al., 2022 [10] |
| United States | CDC National HAI estimates | ~4.5% prevalence; 1.7 million cases annually | CDC, 2022 [9] |
| Central China | Multicenter case-control | 5.8% prevalence | Li et al., 2022 [9] |

Urinary tract infections are the most common type of infection, especially when indwelling catheters

are utilized. Bloodstream infections associated to intravenous lines are the second most common type. Ventilator-associated pneumonias persist in ICUs, and

surgical site infections continue to compromise surgical outcomes despite preventive measures [13]. These infections have a big effect on people's health, finances, and emotions. They endanger not only individual patients but also the integrity of healthcare systems globally, highlighting the pressing necessity for

advanced measures in prevention, detection, and control. Table 1 summarizes reported prevalence rates of HAIs in selected regions and healthcare settings, illustrating substantial variation between high-income and low- and middle-income countries.

Antimicrobial Resistance: Fueling a Silent Pandemic in Hospitals

Antimicrobial resistance (AMR) has emerged as one of the most urgent public health challenges of the 21st century, undermining decades of medical progress. The 2022 Lancet analysis on the global burden of bacterial AMR estimated 4.95 million deaths associated with drug-resistant infections in 2019 alone, with 1.27 million directly attributable to AMR [14]. WHO surveillance data further indicate that resistance rates among priority pathogens such as *Klebsiella pneumoniae*, *Escherichia coli*, *Acinetobacter baumannii*, and *Staphylococcus aureus* are increasing in nearly all regions, with the highest burden in low- and middle-income countries [15].

At the molecular level, pathogens employ several well-characterized mechanisms to evade antimicrobial activity. These include enzymatic inactivation (e.g., β -lactamases, carbapenemases), alteration of drug targets (such as penicillin-binding protein mutations in MRSA), reduced membrane permeability, increased active efflux of antimicrobial agents, and biofilm formation that shields bacteria from both drugs and host immune responses [16]. Resistance traits can be intrinsic or acquired through genetic mutation or, more importantly in healthcare settings, horizontal gene transfer [17]. Horizontal gene transfer — mediated by plasmids, integrons, and transposons — accelerates the spread of resistance determinants within and across bacterial species. Mobile genetic elements frequently carry multiple resistance genes, enabling the rapid emergence of multidrug- and even pan-drug-resistant strains. Genomic investigations of hospital outbreaks have repeatedly traced their origins to plasmid-borne carbapenemase genes or vancomycin resistance operons, highlighting the urgent need for routine molecular surveillance [18], [19].

In hospitals, several factors fuel the persistence and spread of AMR. These include high selection pressure from broad-spectrum antibiotic use (often empirical), frequent use of invasive devices that provide surfaces for biofilm growth, lapses in infection

prevention and control during periods of patient surges, and delays in laboratory detection that allow resistant organisms to circulate undetected. The COVID-19 pandemic amplified many of these drivers, with increased antibiotic prescribing and resource diversion contributing to spikes in certain multidrug-resistant hospital-onset infections.

The clinical consequences are profound: AMR-associated HAIs are linked to higher mortality, prolonged hospital stays, more frequent readmissions, and significantly higher treatment costs. In resource-limited settings, the lack of rapid diagnostics and limited antimicrobial options further exacerbates these impacts.

Given this escalating threat, traditional passive surveillance and delayed laboratory reporting are insufficient. Proactive, technology-enhanced approaches — including real-time genomic sequencing, automated data analytics, and AI-assisted prediction — are increasingly essential to detect, characterize, and respond to resistant pathogens before outbreaks escalate [20], [21].

Specific case examples show how serious the situation is. Extended-spectrum β -lactamase (ESBL) generating Enterobacterales like *Escherichia coli* and *Klebsiella pneumoniae* are increasingly common in many tertiary hospitals across the world. They make whole classes of cephalosporins and penicillins useless. In response, carbapenems—once considered as last-resort agents—have seen growing use, which has, in turn, given rise to carbapenemase-producing organisms (CPOs) such as KPC- and NDM-producing *Klebsiella* and *Enterobacter* spp., now recognized as some of the most serious nosocomial dangers [22]. Even more worrying is the rise of pan-resistant strains, which are bacteria that are resistant to all existing antimicrobials. This has already been seen with *Acinetobacter baumannii* and some CRE isolates. These germs can quickly change normal ICU hospitalizations into deadly situations, forcing doctors to look for

compassionate-use medications and experimental treatments [23].

These factors create a hidden epidemic that is growing behind hospital curtains. Antimicrobial resistance not only makes it harder to treat HAIs, but it also threatens the fundamental foundation of contemporary medicine. The safety of surgery,

chemotherapy, transplantation, and intensive care is seriously compromised without adequate antibiotics. If strong steps aren't taken to stop the development of resistance, enforce stewardship, and use new drugs along with sophisticated surveillance, hospitals may not be able to fight illnesses that they used to readily control. This would be a step backward with terrible effects around the world [20].

Smart Surveillance Technologies: The New Frontier

Surveillance has always been an important part of preventing infections, but the mechanisms that have been used in the past—manual reporting, retrospective chart audits, and irregular laboratory notifications—have not kept up with how quickly and complicated pathogens spread in today's healthcare settings. Traditional surveillance works reactively, counting illnesses after they happen, sending out data on a regular basis, and relying a lot on people being alert. Smart surveillance, on the other hand, is a huge change towards proactive, data-driven defense. Hospitals are changing from passive recorders of outbreaks to predictive guardians who can stop transmission before it gets out of hand by employing technology to collect, assess, and act on real-time information [24].

The technological infrastructure underpinning this revolution is multifaceted. *Electronic Health Records (EHRs)* serve as the foundational layer, aggregating clinical variables such as vital signs, imaging, laboratory diagnostics, antimicrobial prescriptions, and procedural data. When harnessed through automated surveillance platforms, these datasets can be continuously mined for anomalies suggestive of early infection—eliminating delays inherent in manual review processes. In essence, every patient interaction becomes a point of surveillance, quietly feeding into a hospital-wide nervous system attuned to infection risk [25]. To visualize how data flows through a smart surveillance network, Figure 2 maps the interconnected components of a hospital's digital infrastructure and their roles in infection prevention.




Figure 2. Smart Surveillance Ecosystem in Modern Hospitals. This systems diagram illustrates the core components of a smart surveillance infrastructure in hospitals. The central Hospital Information System serves as the nexus, integrating data from Electronic Health Records (EHR), Artificial Intelligence and Machine Learning (AI/ML) analytics, Whole Genome Sequencing (WGS) labs, Internet of Things (IoT) sensors, RFID tracking systems, and the Antimicrobial Stewardship Dashboard to enable real-time infection detection and intervention.

The interpretive power of this data lies increasingly in *Artificial Intelligence (AI)* and *Machine Learning (ML)*. These tools ingest massive, multidimensional datasets to identify complex patterns and correlations. Instead of flagging infections only after microbiological confirmation, AI algorithms can predict outbreak trajectories based on subtle shifts—an uptick in specific antibiotic orders, a cluster of fevers in a particular ward, or deviations from expected recovery trajectories. Such predictive insights allow infection-control teams to deploy interventions (e.g., enhanced

cleaning, cohorting, isolation, or prophylaxis adjustments) in a preemptive, targeted fashion [26].

At the same time, genetic technologies are changing how well we can find things. Whole-Genome Sequencing (WGS) gives a clear picture of microbial "fingerprinting," which lets hospital epidemiologists figure out if two diseases came from the same strain or from different sources. This helps quickly find transmission networks and tell the difference between real outbreaks and random occurrences. Metagenomic sequencing can read all of the genetic material in a sample. It can find organisms that are not expected or cannot be cultured, and it can also find resistance genes before they show up in the phenotype. As sequencing platforms get quicker and cheaper, it's easier to use them for real-time surveillance [27].

Sensor-based technologies from the Internet of Things (IoT) are adding to these analytical capabilities.

Smart hand hygiene systems have sensors that talk to staff ID cards and keep track of how well units are washing their hands [28]. If a unit doesn't wash their hands properly, the system sends rapid feedback. Environmental sensors keep an eye on microbial contamination on surfaces that people touch a lot and in ventilation systems. They let cleaning workers know when they need to act before infections can build up in strongholds. Radio-Frequency Identification (RFID) tags on equipment, staff badges, and patients monitor the movement and contact networks across the hospital environment [29]. This makes it easy to quickly trace exposure pathways if there is a suspected case of cross-transmission. Together, these devices act like millions of eyes and ears, always watching the micro-environment with a level of accuracy that no human worker could match. To facilitate rapid comparison, Table 2 summarizes the key smart surveillance tools discussed above, their primary functions, and documented impacts in healthcare settings.

Table 2. Key Smart Surveillance Tools, Functions, and Documented Impacts

| Tool | Primary Function | Documented Impact |
|--|---|---|
| Electronic Health Records (EHRs) | Aggregate patient data (vitals, labs, imaging, prescriptions) for automated anomaly detection | Reduced detection delays; improved outbreak response speed in NHSN-participating hospitals |
| Artificial Intelligence / Machine Learning (AI/ML) | Predict infection trends from multidimensional datasets | Enabled targeted, preemptive interventions; reduced central-line bloodstream infections in U.S. hospitals |
| Whole-Genome Sequencing (WGS) | Identify microbial strains and resistance genes in real time | Accelerated outbreak source tracing; reduced MRSA and CPE clusters in NHS England |
| Internet of Things (IoT) Sensors | Monitor hand hygiene, environmental contamination, air quality | Improved compliance rates; reduced contamination of high-touch surfaces |
| Radio-Frequency Identification (RFID) | Track movement of staff, patients, and equipment | Enabled rapid contact tracing; halted carbapenem-resistant pathogen outbreaks in Singapore |

Smart surveillance technologies are starting to show real results in healthcare systems all over the world. NHS England has set up digital monitoring platforms with WGS capacity, which help hospitals find and stop MRSA and CPE (carbapenemase-producing Enterobacterales) clusters faster and more effectively than ever before[30]. More and more hospitals in the United States that are part of the CDC's National Healthcare Safety Network (NHSN) are using

automated data feeds and predictive analytics [31]. This has led to fewer catheter-associated urinary tract infections and central-line bloodstream infections. Singapore's health system was the first to use RFID and digital contact tracing throughout the whole institution to stop the spread of carbapenem-resistant pathogens [32]. This method is credited with stopping multiple outbreaks before they could get worse. At the same time, Scandinavian countries have used national health registries and machine-learning decision assistance to

get some of the lowest rates of multidrug-resistant HAIs in the world.

Recent evaluations have quantified the impact of AI-driven surveillance on infection prevention. For example, a multicenter U.S. study using machine learning algorithms integrated with electronic health records demonstrated a 32% reduction in central line-associated bloodstream infections and a 22% reduction in catheter-associated urinary tract infections over 18 months compared to baseline rates [33]. Similarly, in a pilot program in two Singapore tertiary hospitals, AI-based predictive models accurately identified 87% of impending multidrug-resistant organism outbreaks up to 72 hours before conventional methods [34]. These findings underscore that, beyond theoretical promise,

AI-enhanced surveillance can deliver measurable clinical benefits when combined with robust infection prevention practices.

These technologies together herald the beginning of a new era of surveillance, where data flows constantly, signals are analyzed by algorithms, and reactions are quick, accurate, and based on data. As antimicrobial resistance continues to weaken the effectiveness of our treatments, the ability to detect and stop the spread of pathogens before they happen may become the most important thing that keeps hospitals safe. Smart surveillance isn't just an upgrade to our tools; it's a whole new way of thinking about how we keep an eye on, predict, and eventually control the risks we can't see in our wards [35].

Infection Prevention & Control in the Smart Era

Traditional infection prevention and control (IPC) techniques are being redesigned in today's digitally altered hospital context to capitalize on the power of smart surveillance data [36]. Foundational procedures such as thorough hand hygiene, patient isolation, bundle care techniques, and rigorous environmental cleaning remain the cornerstones of IPC, but they are increasingly being optimized via real-time feedback loops [37]. Hand hygiene, which was formerly monitored irregularly by ward observers, can now be recorded continually using sensor-equipped dispensers and badge-linked compliance systems. Isolation techniques are constantly deployed based on predictive data that detect high-risk individuals early, often before clinical symptoms appear [38]. Care bundles for central line care, ventilator use, and urine catheters are audited against live dashboards rather than quarterly reports, allowing teams to intervene quickly when adherence falters. Environmental cleaning has also evolved: pollution reports guide ultraviolet disinfection robots, ATP bioluminescence swabs, and surface-mapping tools, directing resources towards growing hotspots rather than following static timetables [39].

When these established interventions are combined with adaptive protocols informed by surveillance data, their value increases significantly. Rather than relying on blanket treatments, hospitals are increasingly utilizing tailored decolonization tactics, such as screening at-risk patients with quick diagnostics and strategically delivering nasal mupirocin or chlorhexidine washes where they are most effective [40]. Situational alerts created by digital surveillance

platforms warn doctors when patients colonized or infected with resistant pathogens are admitted or transferred, immediately initiating isolation orders and tailored precautions. For example, when microbiology systems discover and electronically flag a patient with carbapenem-resistant *Klebsiella pneumoniae*, automated alerts are sent to bed managers, environmental services and chemists, tightening the net around potential transmission points [41].

Antimicrobial Stewardship Programs (ASPs) play an increasingly important role in the smart IPC environment. Integrating prescribing analytics with resistance surveillance outputs allows stewardship teams to update formulary guidance in real time, encouraging doctors towards narrow-spectrum medicines or alternate regimens as resistance tendencies spike [42]. Smart systems enable the early detection of unsuitable empirical combinations, excessive durations, and duplicated coverage, resulting in "stepped-down" therapy. What was to be a lengthy chart review is now guided by computerized dashboards that span inpatient wards, outpatient clinics, emergency departments, and surgical suites, allowing for more rational antibiotic usage across the whole care continuum. In doing so, ASPs not only slow the development of resistance but also reduce ecological disruption, reducing the risk of opportunistic infections like *Clostridium difficile* [43].

Maintaining such improvements necessitates a continued emphasis on education and behavioral change among healthcare staff. Smart surveillance data

is most effective when it is converted into actionable intelligence for front-line personnel. Real-time feedback panels in staff areas display unit-specific infection trends and compliance performance, promoting transparency and responsibility. Simulation training modules based on recent outbreak scenarios promote a proactive mindset, while targeted reminders and behavior-nudging cues help maintain adherence. Professional development programs now include data interpretation training, resulting in a new breed of infection-control-literate clinicians capable of collaborating with digital systems rather than merely being monitored by them [44].

Ethical, Legal, and Socio-cultural Challenges

As hospitals embrace smart surveillance as a crucial weapon against antimicrobial-resistant illnesses, they must also deal with a complicated set of ethical, legal, and socio-cultural issues. The most pressing of these concerns is privacy and autonomy. Smart surveillance systems rely on the constant aggregation of sensitive patient data (diagnoses, microbiological results, medication histories, and genomic data), generating valid concerns about data security, consent, and potential abuse [20]. Ensuring strong encryption, access restrictions, and governance frameworks is critical to preventing breaches or patient re-identification. At the same time, several systems monitor healthcare personnel directly, recording hand hygiene, patient encounters, and location changes using RFID badges [46]. While essential for infection prevention, such monitoring blurs the distinction between professional accountability and intrusive oversight, raising concerns about autonomy and workplace surveillance [47].

These challenges are exacerbated by algorithmic biases in data interpretation. AI-powered systems are only as effective as the data on which they are trained. Biases caused by skewed data, such as under-representation of minority populations or atypical clinical presentations, might result in false positives, unneeded isolation, or unintentional neglect of persons who do not fit algorithmic standards [48]. Furthermore, hospitals in resource-rich contexts generate significantly more robust datasets than those in low-resource areas, potentially resulting in monitoring technologies that are inapplicable or inaccurate when exported. Institutions that do not provide high-quality data may be marked for risk or excluded from technology breakthroughs, exacerbating

Finally, infection prevention in the smart era moves beyond compliance with static protocols and into an adaptive, learning system in which clinical teams respond dynamically to changing microbial threats. By combining known IPC methods with continuous surveillance, real-time decision support, antimicrobial stewardship, and empowered healthcare personnel, hospitals may go from reacting to infections to preventing them with accuracy. This symbiotic interaction between human vigilance and technology intelligence is at the heart of robust, future-ready healthcare systems that can tackle the ever-changing threats of antimicrobial-resistant HAIs [45].

already existent discrepancies in infection control outcomes [49].

Indeed, worldwide imbalance in access to smart surveillance technologies threatens to exacerbate the digital divide in infection prevention. Wealthy healthcare systems in the Global North are progressively implementing WGS, real-time dashboards, and IoT networks, whereas hospitals in the Global South frequently lack dependable internet connectivity, standardized electronic records, or staff qualified to comprehend complex data outputs. This discrepancy risks resulting in a sort of "digital colonialism," in which surveillance techniques are created, piloted, and perfected in wealthy settings before being exported — without adequate adaptation — to countries with significantly different infrastructural or epidemiological conditions [50]. As seen in Figure 3, worldwide inequalities in digital infrastructure and technological capacity result in uneven preparation for smart surveillance systems.




Figure 3. Global Disparities in Smart Surveillance Readiness. A choropleth world map showing country-level differences in readiness for adopting smart surveillance technologies. Nations are categorized as having high, medium, or low readiness based on infrastructure, data systems, and digital health capabilities. This map illustrates the stark digital divide that may hinder equitable infection control and antimicrobial resistance mitigation.

Finally, the success of any monitoring initiative is dependent on public confidence and transparency. Patients and staff must understand why they are being monitored, how that information is used, and what measures are in place to protect their interests. Clear,

proactive communication of surveillance goals—preventing outbreaks, protecting vulnerable patients, and enhancing care—helps build buy-in while alleviating concerns about punitive or discriminating practices. Without such transparency, even technologically better systems may fail owing to opposition, fear, or disengagement from individuals they are supposed to protect [51].

Achieving the full potential of smart monitoring necessitates not only technological expertise, but also rigorous ethical stewardship—balancing infection prevention with respect for rights, equity, and trust within the medical community.

Challenges Policy and Governance Frameworks

The quick rise of smart surveillance technologies in infection control has led to big changes in policy and governance at the international, national, and institutional levels. Global groups have been very important in establishing conventions and making standards more consistent. The World Health Organization's Global Action Plan on Antimicrobial Resistance stresses the need for integrated surveillance systems and data exchange as key parts of controlling infections. It also encourages member states to use digital tools to improve early detection [52]. The U.S. Centres for Disease Control and Prevention (CDC) has also given detailed instructions for electronic reporting through its National Healthcare Safety Network (NHSN)[53]. The European Union, on the other hand, enforces surveillance reporting requirements through directives like EARS-Net and HAITool, which help make sure that systems work together across borders and set standards [54].

Government-backed stewardship and surveillance programs are very important for effective infection control at the national level. A lot of countries now mandate hospitals to report certain HAIs and resistant infections. This is linked to accreditation or reimbursement programs. The U.S. Hospital-Acquired Condition Reduction Program and the U.K.'s Commissioning for Quality and Innovation (CQUIN) are examples of funding incentives that encourage hospitals to spend money on better data infrastructure and hire more people to watch over it [55]. There are now certification systems for "digital-ready" or "infection-resilient" hospitals. These programs identify hospitals that successfully combine surveillance with IPC and antimicrobial stewardship. Public-private

collaborations are becoming more and more important for innovation and growth [56].

Hospitals, technology suppliers, and pharmaceutical companies working together make it possible to quickly make prototypes of IoT devices, predictive software, and genomic sequencing platforms that are perfect for clinical operations. Industry involvement gives the money and technical know-how needed to establish interoperability standards, cybersecurity tools, and next-generation diagnostics. Healthcare systems, on the other hand, give companies places to test their products and data to improve them. But these alliances need strong governance to protect data ownership, work out intellectual property rights, and make sure that business interests don't get in the way of public health priorities [57].

Overall, achieving effective governance in the smart surveillance era requires a delicate balancing act—aligning technological progress with regulatory oversight, fostering innovation through collaboration, and ensuring that policies remain responsive to evolving epidemiological and ethical realities worldwide.

Future Horizons: Toward Smart, Resilient Hospitals

As hospitals deal with the increasing complexity of illnesses that are resistant to antibiotics, the direction of innovation is towards institutions that are not only reactive but also naturally strong. Central to this trend is the growth of AI-driven decision support systems capable of powering tailored infection control

[58]. Future platforms will go beyond interventions that affect whole populations to provide precision prevention. They will do this by dynamically assessing each patient's risk profile and adjusting prophylaxis, isolation intensity, and environmental controls as needed. Instead of treating all patients in a hospital the same way, algorithms will sort them based on their genomic vulnerability, physiological status, and exposure history. This will make the best use of resources while providing the most protection [20].

The creation of interoperable data ecosystems that go beyond just one institution is very important for this intelligence. When signs of an outbreak appear, interconnected hospital networks and regional health systems can work together to act as early warning systems. Real-time tracking of pathogen transmission between facilities, from long-term care to tertiary centres, will allow for coordinated measures instead of isolated responses. Cloud-based monitoring, shareable antibiograms, and real-time reporting pipelines will be the main tools for keeping everyone in the region up to date on what's going on [59].

But resilience isn't just about technology; it's also about the environment. As climate change changes how infectious diseases spread, hospitals need to use long-lasting new ideas in their infection management. Changes in temperature and humidity can make

pathogens last longer on surfaces, and extreme weather can break supply systems and fill up emergency rooms. It is important to make sure that green hospital programs that make the hospital more energy-efficient, cut down on waste, and make the best use of resources do not put microbiological safety at risk. Advanced HVAC systems, UV sterilization built into air, and eco-friendly disinfectants can help the environment and lower the risk of infection at the same time [60].

Lastly, hospitals of the future will be physically redesigned to be more resistant to infections. Architectural design will put natural light, negative-pressure isolation suites, and modular ward layouts that can easily expand or separate during outbreaks at the top of the list. From the blueprints to the building, airflow engineering, antimicrobial surface materials, and patient flow logistics will be built in. This will turn walls, hallways, and clinical spaces into silent collaborators in infection control. All of these possibilities are coming together to create a new form of hospital: an intelligent, adaptable ecosystem that detects, predicts, and protects against microbial dangers while also protecting the human, environmental, and operational aspects of healthcare delivery [61]. In these kinds of places, infection control will be less of a job and more of a built-in part of the system.

Conclusion

In the past, hospital-acquired infections were manageable problems, but now they are serious dangers because of antibiotic resistance and microbes adapting in ways that have never happened before [62]. These quiet assassins do well in the very places that are supposed to protect life, taking advantage of complicated procedures, weak points in treatment, and blind spots in surveillance. Basic infection control measures are still very important, but the current situation is so urgent that we need to move beyond traditional methods. Smart surveillance technologies, which use real-time analytics, genetic intelligence, AI prediction, and sensor-enabled settings, give us a whole new set of tools. But their promise can only be kept if they are used together with careful infection control measures and smart antimicrobial management. Not

only should the hospital of the future treat infections, it should also be able to see them coming, stop them, and outsmart them [63]. This requires not only investment in technology but also moral vigilance, strong leadership in policy, giving workers more authority, and fairness around the world. The message is clear: healthcare systems need to make smart monitoring a major part of their strategy and put it next to IPC and stewardship to make hospitals that are naturally robust, adaptable, and always learning. Technology alone won't win the war against diseases that people get in hospitals. Instead, it will be a combination of new ideas, constant watchfulness, and responsible leadership. To safeguard, heal, and defend the sanctity of life, we must make sure that every monitor, algorithm, and intervention supports the deeper purpose of medicine

Acknowledgements

AI Assistance Disclosure: Portions of this manuscript's drafting and language refinement were assisted by an

artificial intelligence language model. All content was reviewed, verified, and edited by the authors to ensure accuracy and adherence to the journal's guidelines.

Author Contributions: Olabisi Promise Lawal: Conceptualization, literature search, manuscript drafting, critical revisions, overall supervision. Idris Olumide Orenolu: Writing – review & editing, infection control expertise, literature synthesis. Morayo Anne Ajobiewe: Literature search, drafting (nursing and IPC perspectives), review & editing. Kwesi Akonu Adom Mensah Forson: Writing – review & editing, epidemiological analysis, data interpretation. Ujunwa Favour Agu: Literature contribution (nursing sciences), review & editing. Moses Emmanuel Fidelix: Data curation, drafting (laboratory diagnostics), review & editing. Frances Chinaechekwa Madugba: Contribution to microbiology sections, manuscript review. Lenin Ifeanyi Obi: Drafting (nursing and clinical application), review & editing. All authors read and approved the final manuscript.

Disclosures: The authors declare no conflicts of interest.

Acknowledgments: The authors acknowledge the contributions of all healthcare professionals and institutions whose work and data informed this review. Special thanks to colleagues who provided insights into infection prevention and control practices across diverse healthcare settings.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Ethics Approval: Not applicable. This study is a narrative review and did not involve human participants, animal subjects, or identifiable personal data.

References

- Okonkwo PI, Okafor KC, Garbal JH, Kwaghal BS, Boluwatito B. Hospital Acquired Infections (HAIs) Prevention Practices Among Medical Students in a Teaching Hospital in Jos, Plateau State, Nigeria. *Eur J Med Health Sci*. 2024;6(2):14-20. DOI: 10.24018/ejmed.2024.6.2.1917
- Salam MdA, Al-Amin MdY, Salam MT, Pawar JS, Akhter N, Rabaan AA, et al. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. *Healthcare (Basel)*. 2023;11(13):1946. DOI: 10.3390/healthcare11131946
- Yeung AWK, Torkamani A, Butte AJ, Glicksberg BS, Schuller B, Rodriguez B, et al. The promise of digital healthcare technologies. *Front Public Health*. 2023;11:1196596. DOI: 10.3389/fpubh.2023.1196596
- Kolagari S. Increasing Importance of Florence Nightingale's Theory During the 21st-Century Pandemic Period. *Florence Nightingale J Nurs*. 2023;31(3):215-6. DOI: 10.5152/FNJN.2023.23040
- Poczai P, Karvalics LZ. The little-known history of cleanliness and the forgotten pioneers of handwashing. *Front Public Health*. 2022;10:979464. DOI: 10.3389/fpubh.2022.979464
- Quiros-Roldan E, Sottini A, Natali PG, Imberti L. The Impact of Immune System Aging on Infectious Diseases. *Microorganisms*. 2024;12(4):775. DOI: 10.3390/microorganisms12040775
- World Health Organization. The burden of health care-associated infection worldwide. [Internet]. 2025 [cited 2025 Aug 5]. Available from: <https://www.who.int/news-room/feature-stories/detail/the-burden-of-health-care-associated-infection-worldwide>
- Abubakar U, Amir O, Rodríguez-Baño J. Healthcare-associated infections in Africa: a systematic review and meta-analysis of point prevalence studies. *J Pharm Policy Pract*. 2022;15(1):99. DOI: 10.1186/s40545-022-00498-w
- Li P, Li Y, Zhang Y, Bao J, Yuan R, Lan H, et al. Economic burden attributable to healthcare-associated infections in tertiary public hospitals of Central China: a multi-centre case-control study. *Epidemiol Infect*. 2022;150:e155. DOI: 10.1017/S0950268822001310

10. Harun MdGD, Anwar MMU, Sumon SA, Hassan MZ, Haque T, Mah-E-Muneer S, et al. Infection prevention and control in tertiary care hospitals of Bangladesh: results from WHO infection prevention and control assessment framework (IPCAF). *Antimicrob Resist Infect Control*. 2022;11:125. DOI: 10.1186/s13756-022-01165-0
11. Calfee DP. Methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci, and other Gram-positives in healthcare. *Curr Opin Infect Dis*. 2012;25(4):385-94. DOI: 10.1097/QCO.0b013e3283553441
12. Jump RL. *Clostridium difficile* infection in older adults. *Aging Health*. 2013;9(4):403-14. DOI: 10.2217/ahe.13.37
13. Bouhrour N, Nibbering PH, Bendali F. Medical Device-Associated Biofilm Infections and Multidrug-Resistant Pathogens. *Pathogens*. 2024;13(5):393. DOI: 10.3390/pathogens13050393
14. Murray S, Gale F, Adams D, Dalton L. A scoping review of the conceptualisations of food justice. *Public Health Nutr*. 2023;26(4):725-37. DOI: 10.1017/S1368980022002620
15. Seid M, Bayou B, Aklilu A, Tadesse D, Manilal A, Zakir A, et al. Antimicrobial resistance patterns of WHO priority pathogens at general hospital in Southern Ethiopia during the COVID-19 pandemic, with particular reference to ESKAPE-group isolates of surgical site infections. *BMC Microbiol*. 2025;25:84. DOI: 10.1186/s12866-025-03054-9
16. Tao S, Chen H, Li N, Wang T, Liang W. The Spread of Antibiotic Resistance Genes In Vivo Model. *Can J Infect Dis Med Microbiol*. 2022;2022:3348695. DOI: 10.1155/2022/3348695
17. Yamin D, Uskoković V, Wakil AM, Goni MD, Shamsuddin SH, Mustafa FH, et al. Current and Future Technologies for the Detection of Antibiotic-Resistant Bacteria. *Diagnostics (Basel)*. 2023;13(20):3246. DOI: 10.3390/diagnostics13203246
18. Galgano M, Pellegrini F, Catalano E, Capozzi L, Del Sambro L, Sposato A, et al. Acquired Bacterial Resistance to Antibiotics and Resistance Genes: From Past to Future. *Antibiotics*. 2025;14(3):222. DOI: 10.3390/antibiotics14030222
19. Skender K, Machowska A, Khare S, Singh V, Lundborg CS, Sharma M. Antibiotic prescribing practices, perceived constraints, and views on antimicrobial resistance among general and orthopedic surgeons in central India. *Sci Rep*. 2025;15:25099. DOI: 10.1038/s41598-025-74525-8
20. Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review. *Pharmaceuticals*. 2023;16(11):1615. DOI: 10.3390/ph16111615
21. Kumar NR, Balraj TA, Kempegowda SN, Prashant A. Multidrug-Resistant Sepsis: A Critical Healthcare Challenge. *Antibiotics (Basel)*. 2024;13(1):46. DOI: 10.3390/antibiotics13010046
22. Husna A, Rahman MdM, Badruzzaman ATM, Sikder MH, Islam MR, Rahman MdT, et al. Extended-Spectrum β -Lactamases (ESBL): Challenges and Opportunities. *Biomedicines*. 2023;11(11):2937. DOI: 10.3390/biomedicines11112937
23. Lodise TP, Nguyen ST, Margiotta C, Cai B. Clinical burden of *Acinetobacter baumannii*, including carbapenem-resistant *A. baumannii*, in hospitalized adult patients in the USA between 2018 and 2022. *BMC Infect Dis*. 2025;25(1):549. DOI: 10.1186/s12879-025-12345-2
24. Shenoy ES, Branch-Elliman W. Automating surveillance for healthcare-associated infections: Rationale and current realities (Part I/III). *Antimicrob Steward Healthc Epidemiol*. 2023;3(1):e25. DOI: 10.1017/ash.2023.156
25. Negro-Calduch E, Azzopardi-Muscat N, Krishnamurthy RS, Novillo-Ortiz D. Technological progress in electronic health record system optimization: Systematic review of systematic literature reviews. *Int J Med Inform*. 2021;152:104507. DOI: 10.1016/j.ijmedinf.2021.104507
26. Hudu SA, Alshrari AS, Abu-Shoura EJI, Osman A, Jimoh AO. A Critical Review of the Prospect

- of Integrating Artificial Intelligence in Infectious Disease Diagnosis and Prognosis. *Interdiscip Perspect Infect Dis*. 2025;2025:6816002. DOI: 10.1155/2025/6816002
27. Vashisht V, Vashisht A, Mondal AK, Farmaha J, Alptekin A, Singh H, et al. Genomics for Emerging Pathogen Identification and Monitoring: Prospects and Obstacles. *BioMedInformatics*. 2023;3(4):1145-77. DOI: 10.3390/biomedinformatics3040069
 28. Wu J, Lin Y, Lee S, Chen C, Cheng S, Cheng C, et al. IoT-Based Hand Hygiene Compliance Monitoring System and Validation of Its Effectiveness in Hospital Environments. *Glob Chall*. 2024;8(12):2400124. DOI: 10.1002/gch2.202400124
 29. Profetto L, Gherardelli M, Iadanza E. Radio Frequency Identification (RFID) in health care: where are we? A scoping review. *Health Technol (Berl)*. 2022;12(5):879-91. DOI: 10.1007/s12553-022-00683-6
 30. Fox JM, Saunders NJ, Jerwood SH. Economic and health impact modelling of a whole genome sequencing-led intervention strategy for bacterial healthcare-associated infections for England and for the USA. *Microb Genom*. 2023;9(8):mgen001087. DOI: 10.1099/mgen.0.001087
 31. Shenoy ES, Branch-Elliman W. Automating surveillance for healthcare-associated infections: Rationale and current realities (Part I/III). *Antimicrob Steward Healthc Epidemiol*. 2023;3(1):e25. DOI: 10.1017/ash.2023.156
 32. Obama BM, Grant R, Harbarth S, Buetti N, Catho G. Digitalised measures for the prevention of central line-associated bloodstream infections: a scoping review. *Antimicrob Resist Infect Control*. 2025;14:45. DOI: 10.1186/s13756-025-00945-4
 33. Shenoy S, Jena A, Levinson C, Sharma V, Deepak P, Aswani-Omprakash T, et al. Inflammatory bowel disease in south Asia: a scoping review. *Lancet Gastroenterol Hepatol*. 2025;10(3):259-74. DOI: 10.1016/S2468-1253(24)00356-8
 34. Danchin A. Artificial intelligence-based prediction of pathogen emergence and evolution in the world of synthetic biology. *Microb Biotechnol*. 2024;17(10):e70014. DOI: 10.1111/1751-7915.14399
 35. Yamin D, Uskoković V, Wakil AM, Goni MD, Shamsuddin SH, Mustafa FH, et al. Current and Future Technologies for the Detection of Antibiotic-Resistant Bacteria. *Diagnostics (Basel)*. 2023;13(20):3246. DOI: 10.3390/diagnostics13203246
 36. Arzilli G, De Vita E, Pasquale M, Carloni LM, Pellegrini M, Di Giacomo M, et al. Innovative Techniques for Infection Control and Surveillance in Hospital Settings and Long-Term Care Facilities: A Scoping Review. *Antibiotics*. 2024;13(1):77. DOI: 10.3390/antibiotics13010077
 37. Alhumaid S, Al Mutair A, Al Alawi Z, Alsuliman M, Ahmed GY, Rabaan AA, et al. Knowledge of infection prevention and control among healthcare workers and factors influencing compliance: a systematic review. *Antimicrob Resist Infect Control*. 2021;10:86. DOI: 10.1186/s13756-021-00957-0
 38. Wang C, Jiang W, Yang K, Yu D, Newn J, Sarsenbayeva Z, et al. Electronic Monitoring Systems for Hand Hygiene: Systematic Review of Technology. *J Med Internet Res*. 2021;23(11):e27880. DOI: 10.2196/27880
 39. Sathitakorn O, Jantarathaneewat K, Weber DJ, Apisarnthanarak P, Rutjanawech S, Apisarnthanarak A. Efficacy of Environmental Cleaning Protocol Featuring Real-Time Feedback with and without PX-UV in Reducing the Contamination of Gram-Negative Microorganisms on High-Touch Surfaces in Four Intensive Care Units in Thailand. *Antibiotics (Basel)*. 2023;12(3):438. DOI: 10.3390/antibiotics12030438
 40. Seewald NJ. Adaptive Interventions for a Dynamic and Responsive Public Health Approach. *Am J Public Health*. 2023;113(1):37-9. DOI: 10.2105/AJPH.2022.307187
 41. Bhalla M, Aggarwal A, Fatima KH. Carbapenem-resistant bacteria on hand-

- held and hands-free electronic devices of healthcare workers and non-healthcare workers in Delhi, India. *Infect Prev Pract*. 2021;3(3):100162. DOI: 10.1016/j.infpip.2021.100162
42. Khadse SN, Ugemuge S, Singh C. Impact of Antimicrobial Stewardship on Reducing Antimicrobial Resistance. *Cureus*. 2023;15(12):e49935. DOI: 10.7759/cureus.49935
 43. Intensive Care Society. State of the Art (SOA) 2023 Congress Abstracts. *J Intensive Care Soc*. 2023;24(2 Suppl):1-196. DOI: 10.1177/17511437231183900
 44. Junaid SB, Imam AA, Balogun AO, De Silva LC, Surakat YA, Kumar G, et al. Recent Advancements in Emerging Technologies for Healthcare Management Systems: A Survey. *Healthcare (Basel)*. 2022;10(10):1940. DOI: 10.3390/healthcare10101940
 45. Cornistein W, Santonato D, Novau PA, Fabbro LG, Jorge MF, Malvicini MA, et al. Synergy between infection control and antimicrobial stewardship programs to control carbapenem-resistant Enterobacterales. *Antimicrob Steward Healthc Epidemiol*. 2023;3(1):e162. DOI: 10.1017/ash.2023.437
 46. Perez F, Villegas MV. The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria. *Curr Opin Infect Dis*. 2015;28(4):375-83. DOI: 10.1097/QCO.0000000000000183
 47. Lawal OP, Egwuatu EC, Akanbi KO, Orobator ET, Eweje OZ, Omotayo EO, et al. Fighting Resistance With Data: Leveraging Digital Surveillance to Address Antibiotic Misuse in Nigeria. *Path Sci*. 2025;11(3):1009-17. DOI: 10.22178/pos.96-3
 48. Nazer LH, Zatarah R, Waldrip S, Ke JXC, Moukheiber M, Khanna AK, et al. Bias in artificial intelligence algorithms and recommendations for mitigation. *PLOS Digit Health*. 2023;2(6):e0000278. DOI: 10.1371/journal.pdig.0000278
 49. Zuhair V, Babar A, Ali R, Oduoye MO, Noor Z, Chris K, et al. Exploring the Impact of Artificial Intelligence on Global Health and Enhancing Healthcare in Developing Nations. *J Prim Care Community Health*. 2024;15:21501319241245847. DOI: 10.1177/21501319241245847
 50. Gong E, Wang H, Zhu W, Galea G, Xu J, Yan LL, et al. Bridging the digital divide to promote prevention and control of non-communicable diseases for all in China and beyond. *BMJ*. 2024;387:e076768. DOI: 10.1136/bmj-2023-076768
 51. Fukami T. Enhancing Healthcare Accountability for Administrators: Fostering Transparency for Patient Safety and Quality Enhancement. *Cureus*. 2024;16(8):e66007. DOI: 10.7759/cureus.66007
 52. Garcia R, Barnes S, Boukidjian R, Goss LK, Spencer M, Septimus EJ, et al. Recommendations for change in infection prevention programs and practice. *Am J Infect Control*. 2022;50(12):1281-95. DOI: 10.1016/j.ajic.2022.03.028
 53. Shehab N, Alschuler L, McIlvenna S, Gonzaga Z, Laing A, deRoode D, et al. The National Healthcare Safety Network's digital quality measures: CDC's automated measures for surveillance of patient safety. *J Am Med Inform Assoc*. 2024;31(5):1199-205. DOI: 10.1093/jamia/ocae038
 54. Mader R, Damborg P, Amat JP, Bengtsson B, Bourély C, Broens EM, et al. Building the European Antimicrobial Resistance Surveillance network in veterinary medicine (EARS-Vet). *Euro Surveill*. 2021;26(4):2001359. DOI: 10.2807/1560-7917.ES.2021.26.4.2001359
 55. Feng Y, Kristensen SR, Lorgelly P, Meacock R, Núñez-Elvira A, Rodés-Sánchez M, et al. Pay-for-Performance incentives for specialised services in England: a mixed methods evaluation. *Eur J Health Econ*. 2024;25(5):857-76. DOI: 10.1007/s10198-023-01626-2
 56. Morency-Potvin P, Schwartz DN, Weinstein RA. Antimicrobial Stewardship: How the Microbiology Laboratory Can Right the Ship. *Clin Microbiol Rev*. 2017;30(1):381-407. DOI: 10.1128/CMR.00066-16
 57. Subrahmanya SVG, Shetty DK, Patil V, Hameed BMZ, Paul R, Smriti K, et al. The role of data science in healthcare advancements: applications, benefits, and future prospects. *Ir J*

- Med Sci. 2022;191(4):1473-83. DOI: 10.1007/s11845-021-02784-z
58. Branda F, Scarpa F. Implications of Artificial Intelligence in Addressing Antimicrobial Resistance: Innovations, Global Challenges, and Healthcare's Future. *Antibiotics* (Basel). 2024;13(6):502. DOI: 10.3390/antibiotics13060502
 59. Li L, Back E, Lee S, Shipley R, Mapitse N, Elbe S, et al. Balancing Risks and Opportunities: Data-Empowered-Health Ecosystems. *J Med Internet Res*. 2025;27:e57237. DOI: 10.2196/57237
 60. Uwishema O, Masunga DS, Naisikye KM, Bhanji FG, Rapheal AJ, Mbwana R, et al. Impacts of environmental and climatic changes on future infectious diseases. *Int J Surg*. 2023;109(2):167-70. DOI: 10.1097/JS9.0000000000000231
 61. Łukasik M, Porębska A. Responsiveness and Adaptability of Healthcare Facilities in Emergency Scenarios: COVID-19 Experience. *Int J Environ Res Public Health*. 2022;19(2):675. DOI: 10.3390/ijerph19020675
 62. Lawal O, Elechi K, Adekunle F, Farinde O, Kolapo T, Igbokwe C, et al. A Review on Artificial Intelligence and Point-of-Care Diagnostics to Combat Antimicrobial Resistance in Resource-Limited Healthcare Settings like Nigeria: Review Article. *J Pharm Insights Res*. 2025;3(2):166-75. DOI: 10.53011/jpir.2025.3.2.25
 63. Lawal O, Oyebamiji HO, Kelenna IJ, Chioma FJ, Oyefeso E, Adeyemi BI, et al. A Review on Usage of Digital Health Literacy to Combat Antibiotic Misuse and Misinformation in Nigeria: Review Article. *J Pharm Insights Res*. 2025;3(2):258-69. DOI: 10.53011/jpir.2025.3.2.38